Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies-Reference-Cited by-同舟云学术

Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies

Published:2016-08-30 Issue: Volume:4 Page:e2300
ISSN:2167-8359
Container-title:PeerJ
language:en
Short-container-title:

Author:

Lord Phillip¹,Spiering Rachel²,Aguillon Juan C.³,Anderson Amy E.²,Appel Silke⁴,Benitez-Ribas Daniel⁵,ten Brinke Anja⁶,Broere Femke⁷,Cools Nathalie⁸,Cuturi Maria Cristina⁹,Diboll Julie²,Geissler Edward K.¹⁰,Giannoukakis Nick¹¹,Gregori Silvia¹²,van Ham S. Marieke⁶,Lattimer Staci¹,Marshall Lindsay¹,Harry Rachel A.²,Hutchinson James A.¹⁰,Isaacs John D.²,Joosten Irma¹³,van Kooten Cees¹⁴,Lopez Diaz de Cerio Ascension¹⁵,Nikolic Tatjana¹⁶,Oral Haluk Barbaros¹⁷,Sofronic-Milosavljevic Ljiljana¹⁸,Ritter Thomas¹⁹,Riquelme Paloma¹⁰,Thomson Angus W.²⁰,Trucco Massimo¹¹,Vives-Pi Marta²¹²²,Martinez-Caceres Eva M.²¹²³,Hilkens Catharien M.U.²

Affiliation:

1. School of Computing Science, Newcastle University, Newcastle upon Tyne, United Kingdom

2. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

3. Instituto de Ciencias Biomédicas (ICBM), Universidad de Chile, Santiago, Chile

4. Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway

5. Department of Immunology, Hospital Clínic i Provincial and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain

6. Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands

7. Faculty of Veterinary Medicine, Department of Infectious Diseases and Immunology, Utrecht University, Utrecht, The Netherlands

8. Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium

9. Center for Research in Transplantation and Immunology, ITUN, Inserm UMRS 1064, Nantes, France

10. Department of Surgery, Section of Experimental Surgery, University Hospital Regensburg, Regensburg, Germany

11. Institute of Cellular Therapeutics, Allegheny Health Network, Pittsburgh, PA, United States of America

12. San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Division of Regenerative Medicine, Stem Cells and Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy

13. Department of Laboratory Medicine, Radboud University medical center, Nijmegen, The Netherlands

14. Department of Nephrology, Leiden University Medical Centre, Leiden, The Netherlands

15. Area of Cell Therapy, University Clinic of Navarra, Pamplona, Spain

16. Department of Immunohematology and Blood Transfusion, Leiden University Medical Centre, Leiden, The Netherlands

17. Department of Immunology, Faculty of Medicine, Uludag University, Bursa, Turkey

18. Institute for the Application of Nuclear Energy INEP, University of Belgrade, Belgrade, Serbia

19. Regenerative Medicine Institute (REMEDI), School of Medicine, College of Medicine, Nursing and Health Sciences, National University of Ireland, Galway, Ireland

20. Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America

21. Immunology Division, Germans Trias i Pujol University Hospital and Health Sciences Research Institute, Badalona, Spain

22. CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain

23. Department of Cell Biology, Physiology, Immunology, Universitat Autònoma, Barcelona

Abstract

Cellular therapies with tolerogenic antigen-presenting cells (tolAPC) show great promise for the treatment of autoimmune diseases and for the prevention of destructive immune responses after transplantation. The methodologies for generating tolAPC vary greatly between different laboratories, making it difficult to compare data from different studies; thus constituting a major hurdle for the development of standardised tolAPC therapeutic products. Here we describe an initiative by members of the tolAPC field to generate a minimum information model for tolAPC (MITAP), providing a reporting framework that will make differences and similarities between tolAPC products transparent. In this way, MITAP constitutes a first but important step towards the production of standardised and reproducible tolAPC for clinical application.

Funder

The European Cooperation in Science and Technology (COST)

Publisher

PeerJ

Subject

General Agricultural and Biological Sciences,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://peerj.com/articles/2300.pdf

Reference18 articles.

1. Human tolerogenic DC-10: perspectives for clinical applications;Amodio;Transplantation Research,2012

2. Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis;Bell;Annals of the Rheumatic Diseases,2016

3. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients;Benham;Science Translational Medicine,2015